Meropenem Kabi (Meropenem Trihydrate)

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria.

• Complicated intra‑abdominal infections: provides rapid bactericidal activity to eradicate pathogens and resolve infection.
• Complicated urinary tract infections: eliminates causative organisms and helps restore urinary tract sterility.
• Hospital‑acquired pneumonia: targets resistant Gram‑negative and Gram‑positive bacteria to improve pulmonary outcomes.
• Ventilator‑associated pneumonia: delivers high tissue concentrations to treat ventilator‑related lung infections.
• Meningitis: penetrates the cerebrospinal fluid to achieve therapeutic levels against meningitic pathogens.
• Severe sepsis and septic shock: offers broad coverage to control systemic infection and support hemodynamic recovery.

• Meropenem exerts its antibacterial effect by binding to multiple penicillin‑binding proteins (PBPs) on the bacterial cell wall. This inhibits the final transpeptidation step of peptidoglycan synthesis, leading to a weakened cell wall and osmotic lysis. The drug’s high affinity for PBPs and resistance to most β‑lactamases confer a broad spectrum of bactericidal activity against Gram‑negative, Gram‑positive and anaerobic organisms.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset reported in many patients.
• Diarrhea: loose stools, occasionally leading to dehydration.
• Rash: skin erythema or pruritus without systemic involvement.
• Infusion site reactions: erythema, pain or phlebitis at the injection site.
• Elevated liver enzymes: transient increases in ALT or AST.
• Headache: mild to moderate head discomfort.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or pre‑existing CNS disorders.
• Clostridioides difficile‑associated diarrhea: severe colitis requiring specific therapy.
• Anaphylaxis: acute, life‑threatening hypersensitivity reaction.
• Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Thrombocytopenia: marked reduction in platelet count.

Before initiating Meropenem therapy, clinicians should consider several safety precautions.

• Assess renal function: dose adjustment may be required in patients with impaired clearance.
• Monitor for seizures: risk increases in renal failure, CNS disease or high‑dose therapy.
• Review allergy history: avoid use in patients with known hypersensitivity to β‑lactams.
• Adjust for hepatic impairment: consider reduced dosing in severe liver disease.
• Use cautiously in neonates and infants: limited data require careful monitoring.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: carbapenems markedly reduce serum valproate concentrations, risking seizure breakthrough.
• Concurrent carbapenem therapy: additive toxicity and no clinical benefit from overlapping agents.
• High‑dose aminoglycosides: increased risk of nephrotoxicity when combined with Meropenem.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate renal dysfunction; monitor kidney function and electrolytes.
• NSAIDs: potential additive renal impairment; assess renal status regularly.
• Warfarin: carbapenems may enhance anticoagulant effect; check INR more frequently.
• Phenytoin: possible alteration of plasma levels; monitor seizure control.